Search PubMed⌕ Search

Biomedical subjects

M Miki

Publications and source records attributed to M Miki.

At least 253 records · Page 14Linked to original sources
PubMed1981

Clinical evaluation of serum ferritin to iron ratio in malignant diseases.

Serum ferritin levels were measured in 72 normal subjects and in 214 cases with various diseases by an immunoradiometric assay. In normal subjects, the serum ferritin levels were 27-230 mg/ml. Elevated serum ferritins were observed in most cases with iron excess and acute hepatitis. Markedly elevated levels were found in the majority of cases with acute leukemia, malignant lymphoma, hepatoma, and pancreatic cancer. High ferritin levels were also found in other malignant diseases. However, the range overlapped broadly with that of nonmalignant diseases. The serum ferritin correlated significantly with serum iron in normals and in those with iron deficiency anemia. In most nonmalignant cases, the serum ferritin and iron levels distributed on a regression line obtained from levels in normals and those with iron deficiency anemia. However, 92% of the malignant cases showed a serum ferritin to iron ratio higher than that of normal subjects. The estimation of the serum ferritin to iron ratio is a useful means for screening patients or in the differential diagnosis of a suspected malignant lesion.

Adult↗
PubMed1981

Determination of a new hypoglycemic drug, gliclazide, in human serum by radioimmunoassay.

radioimmunoassays have been developed which enable accurate and sensitive determination of gliclazide in human serum. Antisera A and B against gliclazide were obtained from guinea pigs immunized with conjugates A and B prepared by coupling gliclazide homologues, 1-(p-toluenesulfonyl)-3-(4'-carboxypiperidino)urea and 1-(4-methyl-3-carboxybenzenesulfonyl)-3-(3-azabicyclo[3,3,0]oct-3-yl)urea, to bovine serum albumin. 3H-Gliclazide was used as a tracer. Dextran-coated charcoal was used to separate bound and free 3H-gliclazide in the reaction mixture. The assays of gliclazide in serum were possible over a concentration range from 0.25 to 20 microgram/ml with the antiserum A and from 0.1 to 10 microgram/ml with the antiserum B, respectively, using 0.01 ml of human serum without the need for an extraction procedure. The antisera used for the assays were specific for gliclazide. Data obtained by the radioimmunoassay with the antiserum A are in good agreement with those by the radioimmunoassay with the antiserum B and gas-liquid chromatography. Serum levels of gliclazide in healthy volunteers receiving single oral dosing (40 mg/subject) have also been determined.

Antibody Specificity↗
PubMed1980

[The development of determining human prostatic acid phosphatase by radioimmunoassay (author's transl)].

We purified human prostatic acid phosphatase (hPAP) from prostatic tissues by affinity chromatography, DEAE cellulose and gel filtration and also examined physicochemical properties of highly purified PAP. We developed a double-antibody radioimmunoassay for hPAP in serum, with use of antiserum raised in rabbit against highly purified PAP. The antiserum did not cross react with acid phosphatase from platelets and red blood cells. Experimental detail are outlined to assess the reproducibility and reliability of the method under various conditions. The upper limit of the serum PAP levels in the present assay was set at 3.0 ng/ml by 162 determinations of samples. The serum PAP levels of 2 untreated patients with prostatic carcinoma were higher than 3.0 ng/ml and 39 patients with benign prostatic hyperplasia were an average value of 1.9 ng/ml.

Acid Phosphatase↗